Comparison of three different recombinant hepatitis B vaccines: GeneVac-B, Engerix B and Shanvac B in high risk infants born to HBsAg positive mothers in India

World Journal of Gastroenterology

Volumn 13, Issue 22, 2007, Pages 3084-3089

  Velu, Vijayakumar ^a,b,e   Nandakumar, Subhadra ^a,e   Shanmugam, Saravanan ^a,c,e   Jadhav, Suresh Sakharam ^d   Kulkarni, Prasad Suryakant ^d   Thyagarajan, Sadras Panchatcharam ^a,c,e  

^a UNIVERSITY OF MADRAS   (India)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^d Serum Institute of India Ltd   (India)

^e National Referral Centre for Viral Hepatitis   (India)

Author keywords

GeneVac B; High risk infants; Infant vaccination; Maternal screening

Indexed keywords

GENEVAC B; HEPATITIS B SURFACE ANTIGEN; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANTIBODY TITER; ARTICLE; CHILD CARE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CRYING; DRUG COST; DRUG ERUPTION; DRUG SAFETY; EARLY INTERVENTION; FEVER; FOLLOW UP; HEPATITIS B; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; INDIA; INFANT; INFANT DISEASE; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; IRRITABILITY; MAJOR CLINICAL STUDY; MATERNAL WELFARE; MULTICENTER STUDY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SEROCONVERSION; SIDE EFFECT; SKIN INDURATION; SYSTEMIC DISEASE; VACCINATION; VIRUS TRANSMISSION;

EID: 34447289377     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i22.3084     Document Type: Article

References (37)

1. Maddrey WC. Hepatitis B: an important public health issue. J Med Virol 2000; 61: 362-366
2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745
3. Yao JL. Perinatal transmission of hepatitis B virus infection and vaccination in China. Gut 1996; 38 Suppl 2: S37-S38
4. Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975; 292: 771-774
5. Akhter S, Talukder MQ, Bhuiyan N, Chowdhury TA, Islam MN, Begum S. Hepatitis B virus infection in pregnant mothers and its transmission to infants. Indian J Pediatr 1992; 59: 411-415
6. Okada K, Kamiyama I, Inomata M, Imai M, Miyakawa Y. e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med 1976; 294: 746-749
7. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977; 105: 94-98
8. Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY, Chen CL. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983; 2: 1099-1102
9. Nayak NC, Panda SK, Zuckerman AJ, Bhan MK, Guha DK. Dynamics and impact of perinatal transmission of hepatitis B virus in North India. J Med Virol 1987; 21: 137-145
10. Aggarwal R, Ranjan P. Preventing and treating hepatitis B infection. BMJ 2004; 329: 1080-1086
11. Beasley RP, Hwang LY. Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J Infect Dis 1983; 147: 185-190
12. Nair PV, Weissman JY, Tong MJ, Thursby MW, Paul RH, Henneman CE. Efficacy of hepatitis B immune globulin in prevention of perinatal transmission of the hepatitis B virus. Gastroenterology 1984; 87: 293-298
13. Kulkarni PS, Raut SK, Patki PS, Phadke MA, Jadhav SS, Kapre SV, Dhorje SP, Godse SR. Immunogenicity of a new, low-cost recombinant hepatitis B vaccine derived from Hansenula polymorpha in adults. Vaccine 2006; 24: 3457-3460
14. Vijayakumar V, Hari R, Parthiban R, Mehta J, Thyagarajan SP. Evaluation of immunogenicity and safety of GeneVac-B: a new recombinant hepatitis B vaccine in comparison with Engerix B and Shanvac B in healthy adults. Ind J Med Microbiol 2004; 22: 34-38
15. Vijayakumar V, Shraddha M, Subhadra N, Saravanan S, Sundararajan T, Thyagarajan SP. Immunogenicity and safety of 10 mg and 20 mg doses of GeneVac-B, a recombinant hepatitis B vaccine, in healthy adolescents. Indian J Gastroenterol 2004; 23: 34-35
16. Kakrani AL, Bharadwaj R, Karmarkar A, Joshi S, Yadav S, Bhardwaj S, Kulkarni P, Kulkarni S. Immune responses induced by two close strengths of an yeast-derived recombinant hepatitis B vaccine in adolescents. Indian J Gastroenterol 2003; 22: 71-72
17. Velu V, Nandakumar S, Shanmugam S, Thyagarajan SP. Persistence of anti-HBs titers after two different doses of GeneVac-B, a recombinant hepatitis B vaccine, in healthy adolescents. Indian J Gastroenterol 2007; 26: 48
18. Shivananda, Somani V, Srikanth BS, Mohan M, Kulkarni PS. Comparison of two hepatitis B vaccines (GeneVac-B and Engerix-B) in healthy infants in India. Clin Vaccine Immunol 2006; 13: 661-664
19. Sapru A, Kulkarni IX3, Bhave S, Bavdekar A, Naik SS, N Pandit AN. Immunogenicity and Reactogenicity of Two Recombinant Hepatitis B Vaccines in Small Infants: A Randomized, Double-Blind Comparative Study. J Trop Pediatr 2007; Epub ahead of print
20. Margolis HS. Prevention of acute and chronic liver disease through immunization: hepatitis B and beyond. J Infect Dis 1993; 168: 9-14
21. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336: 196-204
22. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991; 40: 1-25
23. Freed GL, Bordley WC, Clark SJ, Konrad TR. Reactions of pediatricians to a new Centers for Disease Control recommendation for universal immunization of infants with hepatitis B vaccine. Pediatrics 1993; 91: 699-702
24. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995; 20: 992-1000
25. Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975; 292: 771-774
26. Hyams KC, Osman NM, Khaled EM, Koraa AA, Imam IZ, el-Ghorab NM, Dunn MA, Woody JN. Maternal-infant transmission of hepatitis B in Egypt. J Med Virol 1988; 24 191-197
27. Basalamah AH, Serebour F, Kazim E. Materno-foetal transmission of hepatitis B in Saudi Arabia. J Infect 1984; 8: 200-204
28. Botha JF, Ritchie MJ, Dusheiko GM, Mouton HW, Kew MC. Hepatitis B virus carrier state in black children in Ovamboland: role of perinatal and horizontal infection. Lancet 1984; 1: 1210-1212
29. Hsu HM, Lu CF, Lee SC, Lin SR, Chen DS. Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization. J Infect Dis 1999; 179: 367-370
30. Prakash C, Sharma RS, Bhatia R, Verghese T, Datta KK. Prevalence of North India of hepatitis B carrier state amongst pregnant women. Southeast Asian J Trop Med Public Health 1998; 29: 80-84
31. Mittal SK, Rao S, Rastogi A, Aggarwal V, Kumari S. Hepatitis B - potential of perinatal transmission in India. Trop Gastroenterol 1996; 17: 190-192
32. Gupta I, Sehgal A, Sehgal R, Ganguly NK. Vertical transmission of hepatitis B in north India. J Hyg Epidemiol Microbiol Immunol 1992; 36: 263-267
33. Gill HH, Majumdar PD, Dhunjibhoy KR, Desai HG. Prevalence of hepatitis B e antigen in pregnant women and patients with liver disease. J Assoc Physicians India 1995; 43: 247-248
34. Biswas SC, Gupta I, Ganguly NK, Chawla Y, Dilawari JB. Prevalence of hepatitis B surface antigen in pregnant mothers and its perinatal transmission. Trans R Soc Trop Med Hyg 1989; 83: 698-700
35. Schiff GM, Sherwood JR, Zeldis JB, Krause DS. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. J Adolesc Health 1995; 16: 12-17
36. Halsey NA, Moulton LH, O'Donovan JC, Walcher JR, Thoms ML, Margolis HS, Krause DS. Hepatitis B vaccine administered to children and adolescents at yearly intervals. Pediatrics 1999; 103: 1243-1247
37. Heron LG, Chant KG, Jalaludin BB. A novel hepatitis B vaccination regimen for adolescents: two doses 12 months apart. Vaccine 2002; 20: 3472-3476